This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ELCC, GENEVA, 11 - 14 APRIL 2018

Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7

James C.-H. Yang, Yi-Long Wu, Vera Hirsh, Kenneth O’Byrne, Nobuyuki Yamamoto, Sanjay Popat, Akihiro Tamiya, Angela Märten, Martin Schuler

ELCC 2018 CNS Poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.

Schuler M et al. J Thorac Oncol. 2016 Mar;11(3):380-90.

Watch Vera Hirsh's opinion on the treatment of brain metastases!

Vera Hirsh

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Girard et al, Future Oncol – Online ahead of print DOI: 10.2217/fon-2017-0636

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Paz-Ares et al. Annals of Oncology 28: 270–277, 2017

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang et al Lancet Oncology, The, 2015-02-01, Volume 16, Issue 2, Pages 141-151

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

ELCC 2018

Find information on Boehringer Ingelheim's clinical data and activities at ELCC 2018
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.